Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q3 FY25 results · Oct–Dec 2024
Dr. Lal Path Labs reported revenue from operations of ₹596.70 crore (up 10.7% from Q3 FY24) and net profit of ₹98.10 crore (up 19.3% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 596.70 | 538.90 | +10.7% | 660.20 | −9.6% |
| Other income | 25.10 | 18.30 | +37.2% | 21.90 | +14.6% |
| Total income | 621.80 | 557.20 | +11.6% | 682.10 | −8.8% |
| Profit before tax | 138.30 | 115.90 | +19.3% | 183.10 | −24.5% |
| Net profit for the period | 98.10 | 82.20 | +19.3% | 130.80 | −25.0% |
| Attributable to shareholders of the company | 96.70 | 81.30 | +18.9% | 129.20 | −25.2% |
| EPS, basic (₹) | 11.60 | 9.77 | +18.7% | 15.52 | −25.3% |
| Net margin (%) | 16.4 | 15.3 | 19.8 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 528.10 | 476.00 | +10.9% | 583.90 | −9.6% |
| Other income | 29.50 | 15.10 | +95.4% | 22.00 | +34.1% |
| Total income | 557.60 | 491.10 | +13.5% | 605.90 | −8.0% |
| Profit before tax | 151.20 | 119.50 | +26.5% | 183.30 | −17.5% |
| Net profit for the period | 114.50 | 88.30 | +29.7% | 135.20 | −15.3% |
| EPS, basic (₹) | 13.74 | 10.78 | +27.5% | 16.24 | −15.4% |
| Net margin (%) | 21.7 | 18.6 | 23.2 |
Consolidated
- Filed with BSE
- 30 Jan 2025, 18:53 IST
- Board meeting
- 30 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jan 2025, 18:53 IST
- Board meeting
- 30 Jan 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE